Copertina

NUP98 oncofusions in myeloid malignancies: An update on molecular mechanisms and therapeutic opportunities

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Milad Rasouli, Selina Troester, Florian Grebien, Bianca F. Goemans, C. Michel Zwaan, Olaf Heidenreich
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2024
Soggetti:	HemaSphere
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Oncogenic and immunological targets for matched therapy of pediatric blood cancer patients: Dutch iTHER study experience
di: Judith M. Boer, et al.
Pubblicazione: (2024)

Dual specific STAT3/5 degraders effectively block acute myeloid leukemia and natural killer/T cell lymphoma
di: Daniel Pölöske, et al.
Pubblicazione: (2024)

Isatuximab in combination with chemotherapy for pediatric patients with relapsed/refractory acute lymphoblastic leukemia or acute myeloid leukemia: The ISAKIDS study
di: André Baruchel, et al.
Pubblicazione: (2025)

Inflammatory signaling in the pathogenesis of acute myeloid leukemia
di: Artemis Margrith Baumann, et al.
Pubblicazione: (2025)

An EHA strategic roadmap for improved care in Europe for AYA patients with malignant and chronic non‐malignant hematological diseases
di: Anna Castleton, et al.
Pubblicazione: (2026)

Less is more: Depleting myeloid‐biased HSCs to restore immune function
di: Hansen J. Kosasih, et al.
Pubblicazione: (2024)

Open or closed? Understanding the molecular mechanisms and clinical implications of ADAMTS13's conformation
di: Quintijn Bonnez, et al.
Pubblicazione: (2025)

Combination of targeted pharmacotherapy and immunotherapy with anti‐CD19 CAR NK cells in acute lymphoblastic leukemia
di: Hanna Kirchhoff, et al.
Pubblicazione: (2025)

Inflammatory disorders in IDH‐mutated myeloid neoplasms: Characteristics and response to IDH inhibitors
di: Romain Stammler, et al.
Pubblicazione: (2025)

Upregulation of ALDH1 as an adaptive epigenetic response to anthracyclines in acute myeloid leukemia
di: Francesco Leonetti, et al.
Pubblicazione: (2025)

Harnessing the immunotherapeutic potentials of gamma delta T cells against hematological malignancies
di: Charles Agbuduwe, et al.
Pubblicazione: (2025)

Cell surface surprise: NPM1 is an immune therapy target for acute myeloid leukemia
di: Hansen J. Kosasih, et al.
Pubblicazione: (2025)

HLA diversity is associated with TKI response and treatment‐free remission in chronic myeloid leukemia
di: Charles Toulemonde, et al.
Pubblicazione: (2025)

European Cancer Organisation Essential Requirements for Quality Cancer Care: Hematological malignancies
di: John G. Gribben, et al.
Pubblicazione: (2025)

Neuroinflammatory changes in acute myeloid leukemia: Evidence for blood–brain barrier disruption and glial activation
di: Marta Febo, et al.
Pubblicazione: (2026)

Integrating transcriptomic profiling and machine learning: A clinically actionable prognostic model for infant acute myeloid leukemia
di: Yu Tao, et al.
Pubblicazione: (2025)

Imlifidase for hematologists: Creating a therapeutic window in the presence of neutralizing alloantibodies
di: Roger E. G. Schutgens
Pubblicazione: (2024)

Disease characteristics and outcomes of acute myeloid leukemia in germline RUNX1 deficiency (Familial Platelet Disorder with associated Myeloid Malignancy)
di: Martijn P. T. Ernst, et al.
Pubblicazione: (2025)

Realizing precision medicine in chronic lymphocytic leukemia: Remaining challenges and potential opportunities
di: Kostas Stamatopoulos, et al.
Pubblicazione: (2024)

Dynamics of BCR::ABL1 transcript levels and clinical outcomes after switch to second‐line therapy in pediatric chronic myeloid leukemia
di: Stephanie Sembill, et al.
Pubblicazione: (2026)

Refinement of the prognostic impact of somatic CEBPA bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)
di: Frank G. Rücker, et al.
Pubblicazione: (2024)

Models for the marrow: A comprehensive review of AI‐based cell classification methods and malignancy detection in bone marrow aspirate smears
di: Tabita Ghete, et al.
Pubblicazione: (2024)

T‐cell lymphoblastic lymphoma in constitutional mismatch repair deficiency (CMMRD): Exploring treatment opportunities
di: Emma Kroeze, et al.
Pubblicazione: (2024)

Immunophenotypic abnormality quantification refines multiparameter flow cytometry‐based measurable residual disease testing in adults allografted for acute myeloid leukemia in morphologic remission
di: Calvin M. Le, et al.
Pubblicazione: (2026)

A cellular reporter system to evaluate endogenous fetal hemoglobin induction and screen for therapeutic compounds
di: Thijs C. J. Verheul, et al.
Pubblicazione: (2024)

Mortality in patients with lymphoid malignancies and multiple myeloma was stable upon and during the COVID‐19 pandemic: A population‐based, nation‐wide study
di: Tereza Faitová, et al.
Pubblicazione: (2024)

Myb overexpression synergizes with the loss of Pten and is a dependency factor and therapeutic target in T‐cell lymphoblastic leukemia
di: André Almeida, et al.
Pubblicazione: (2024)

Implementation science in hemato‐oncology molecular diagnostics in France via the Groupe des Biologistes Moléculaire des Hémopathies Malignes (GBMHM)
di: Jean‐Michel Cayuela, et al.
Pubblicazione: (2025)

PRC2‐mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and monosomy 7
di: Hiroyoshi Kunimoto, et al.
Pubblicazione: (2025)

Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA
di: Christian M. Vonk, et al.
Pubblicazione: (2024)

Response to therapy and prognosis according to molecular characterization in CALR ‐mutated essential thrombocythemia
di: Marta Santaliestra, et al.
Pubblicazione: (2026)

Age‐stratified machine learning identifies divergent prognostic significance of molecular alterations in AML
di: Jan‐Niklas Eckardt, et al.
Pubblicazione: (2025)

Integrating AIPSS‐MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis
di: Adrián Mosquera‐Orgueira, et al.
Pubblicazione: (2024)

Ex vivo drug responses and molecular profiles of 597 pediatric acute lymphoblastic leukemia patients
di: Anna Pia Enblad, et al.
Pubblicazione: (2025)

Unraveling the role of TP53 mutations in myeloproliferative neoplasms: Molecular mechanisms of leukemic transformation
di: Suzana da Silva‐Benedito, et al.
Pubblicazione: (2026)

Casein kinase 1δ/ε inhibition suppresses CLL proliferation through cell‐intrinsic and microenvironmental mechanisms
di: Antonia Mikulova, et al.
Pubblicazione: (2026)

Exploring the molecular biomarker utility of circCCT3 in multiple myeloma: A favorable prognostic indicator, particularly for R‐ISS II patients
di: Maria Papatsirou, et al.
Pubblicazione: (2024)

Event‐free survival in early polycythemia vera patients correlates with molecular response to ropeginterferon alfa‐2b or hydroxyurea/best available therapy (PROUD‐PV/CONTINUATION‐PV)
di: Jean‐Jacques Kiladjian, et al.
Pubblicazione: (2025)

Extracellular vesicles from chronic lymphocytic leukemia cells promote leukemia aggressiveness by inducing the differentiation of monocytes into nurse‐like cells via an RNA‐dependent mechanism
di: Nathan Dubois, et al.
Pubblicazione: (2025)

Hematology in times of crisis: Lessons learned and strategic priorities from the EHA–ASH Joint Workshop on Ukraine
di: Oleksandr Istomin, et al.
Pubblicazione: (2026)